Powerful Parliamentary Committee Slams India’s Drug Regulator; Calls For Swift Overhaul
This article was originally published in PharmAsia News
The committee unravels a system full of questionable practices and recommends complete overhaul of India’s drug regulator.
You may also be interested in...
MUMBAI - An eerie uncertainty looms over the future of India's highest and most powerful drug authority, the Drug Controller General of India, as the government was challenged last week against its decision to grant a nine-month service term extension to the present incumbent Surinder Singh
MUMBAI - After building great expectations on allowing Phase I human studies in India, the government has now back tracked from taking any concrete decisions until the "right infrastructure" is put in place
Drug Controller General Of India Surinder Singh On India’s Regulatory Overhaul: An Interview With PharmAsia News
Surinder Singh took the mantle of the Drug Controller General of India a few months ago. From being a microbiologist to handling the most important regulatory position in the Indian drug industry, Singh is already confronted with a host of challenges. Overhauling the regulatory system, dealing with vexatious registration issues and advocating for Indian drug industry on global forums, Singh has been working on an extremely tight schedule. Singh took time off from his busy routine and sat down with PharmAsia News' India bureau to discuss India's impending regulatory overhaul (PharmAsia News, Sept. 11, 2008).